Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 64 of 64 results for etanercept

  1. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    27 March 2002

  2. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

    Technology appraisal guidance
    Published
    27 March 2002

  3. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  4. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued